Advaxis Appoints Anthony Lombardo as Chief Business Officer
April 19, 2017 08:00 ET
|
Advaxis
PRINCETON, N.J., April 19, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced that Anthony A. Lombardo, an industry...
Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
March 27, 2017 08:00 ET
|
Advaxis
PRINCETON, N.J., March 27, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at...
EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer
March 23, 2017 08:00 ET
|
Advaxis
PRINCETON, N.J., March 23, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced the European Medicines Agency (EMA) issued...
Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer
March 15, 2017 07:00 ET
|
Advaxis
- Achieved primary objective of 12-month survival rate, demonstrating axalimogene filolisbac is an active therapy in metastatic cervical cancer - Unprecedented 12-month survival rate for metastatic...
Advaxis to Present at the 2017 Barclays Global Healthcare Conference
March 13, 2017 08:00 ET
|
Advaxis
PRINCETON, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced that Sara Bonstein, Chief Financial...
Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical
March 07, 2017 08:00 ET
|
Advaxis
PRINCETON, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Al Blunt, M.D., has joined...
Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO
March 06, 2017 06:00 ET
|
Advaxis
PRINCETON, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug...
Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
March 02, 2017 08:00 ET
|
Advaxis
PRINCETON, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, will host a Research Reception during the...
Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
February 27, 2017 08:00 ET
|
Advaxis
PRINCETON, N.J., and HAMILTON, Bermuda, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS) and SELLAS Life Sciences Group, both late-stage biopharmaceutical companies focused on...
Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer
February 06, 2017 08:00 ET
|
Advaxis
PRINCETON, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient has been...